Caleb Rans

Contributing Writer https://www.cancertherapyadvisor.com

Caleb Rans is a clinical pharmacist and medical communications specialist with professional expertise in medical writing, editing, and contract clinical research. He holds a PharmD from the University of Alberta and presently resides in Vancouver, Canada. He currently works as an independent consultant for several news, CME, and pharmaceutical companies.

All articles by Caleb Rans

Hematologic Cancers

Clonal Hematopoiesis in Hematologic Malignancies, Bone Marrow Failure Syndromes, and Stem Cell Clones

Caleb Rans

September 2, 2020

Recent studies have better elucidated the link between clonal hematopoiesis and hematologic malignancies.

This fact sheet provides an overview of the updated ESMO clinical practice guideline for hereditary GI cancers.

General Oncology

New ASCO Clinical Guidelines on Management of Cancer Cachexia

Caleb Rans

June 25, 2020

The American Society of Clinical Oncology published new clinical guidelines on the management of cachexia in adults with advanced cancer.

A doctor shows a tablet to an elderly patient

Hematologic Cancers

Current and Prospective Treatment Options for Waldenström Macroglobulinemia

Caleb Rans

February 7, 2020

Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia.

Lymphoma

Determining Prognosis for Patients With Diffuse Large B-Cell Lymphoma

Caleb Rans

October 23, 2019

Researchers summarized the novel techniques and models currently being developed to improve prognostication in diffuse large B-cell lymphoma.

The use of real-world data shows promise in guiding the development of management strategies for lymphoid malignancies.

Lymphoma

Real-World Data in the Era of Precision Medicine for Lymphoid Malignancies

Caleb Rans

August 15, 2019

The use of real-world data shows promise in guiding the development of management strategies for lymphoid malignancies.

The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.

Hematologic Cancers

Evaluating the Cost-Effectiveness of Acute Myeloid Leukemia Treatment

Caleb Rans

June 19, 2019

The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.

White blood cells attacking cancer cells

Hematologic Cancers

Restoring T-Cell Immunity Following Allogeneic Hematopoietic Stem Cell Transplantation

Caleb Rans

April 26, 2019

Though adoptive T-cell transfer has demonstrated clinical applicability, many barriers prevent it from becoming a standard of care following transplant.

Hematologic Cancers

Direct-Acting Oral Anticoagulant Treatment for Acute Venous Thromboembolism

Caleb Rans

April 8, 2019

Although clinical trials are ongoing, the safety profile and net clinical benefit of DOACs for acute venous thromboembolism treatment are unclear.

Next post in Hematologic Cancers